Agenus Inc (NASDAQ:AGEN) shares dropped 7.1% during mid-day trading on Monday . The stock traded as low as $1.82 and last traded at $1.83. Approximately 1,278,390 shares changed hands during trading, a decline of 16% from the average daily volume of 1,519,452 shares. The stock had previously closed at $1.97.

AGEN has been the topic of several recent research reports. BidaskClub cut shares of Agenus from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th.

The company has a debt-to-equity ratio of -0.11, a quick ratio of 1.32 and a current ratio of 1.32. The firm has a market capitalization of $217.50 million, a PE ratio of -1.57 and a beta of 1.70.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.16. equities analysts expect that Agenus Inc will post -1.2 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in AGEN. Jane Street Group LLC purchased a new stake in shares of Agenus during the second quarter valued at about $101,000. A.R.T. Advisors LLC purchased a new stake in shares of Agenus during the first quarter valued at about $103,000. Russell Investments Group Ltd. purchased a new stake in shares of Agenus during the first quarter valued at about $197,000. Blair William & Co. IL lifted its position in shares of Agenus by 46.6% during the first quarter. Blair William & Co. IL now owns 48,810 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 15,510 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Agenus by 95.8% during the first quarter. Barclays PLC now owns 73,955 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 36,179 shares during the last quarter. 35.34% of the stock is owned by institutional investors and hedge funds.

About Agenus (NASDAQ:AGEN)

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.